Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.

ABSTRACT:

Importance

There is a strong rationale for treating sarcomas with immunotherapy.

Objective

To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas.

Design, setting, and participants

This was an open-label, multicenter, phase 2 study of 4 cohorts of patients with advanced soft-tissue sarcoma (STS), including leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), other sarcomas (others), and gastrointestinal stromal tumor (GIST). All patients received 50 mg twice daily cyclophosphamide 1 week on and 1 week off and 200 mg of intravenous pembrolizumab every 3 weeks.

Intervention or exposure

Pembrolizumab in combination with metronomic cyclophosphamide.

Main outcomes

SUBMITTER: Toulmonde M 

PROVIDER: S-EPMC5833654 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature